Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung CancerGlobeNewsWire • 04/08/22
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual MeetingGlobeNewsWire • 03/08/22
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid LeukemiaGlobeNewsWire • 01/20/22
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 12/16/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURAPRNewsWire • 12/13/21
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell LymphomaGlobeNewsWire • 12/13/21
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with VenetoclaxGlobeNewsWire • 12/13/21
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid LeukemiaGlobeNewsWire • 11/24/21
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/07/21
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/07/21